A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Massachusetts General Hospital
Virtual Tribunal Monastery
Center for International Blood and Marrow Transplant Research
Washington University School of Medicine
New York Medical College
Duke University
Roswell Park Cancer Institute
University of Aberdeen
Columbia University
Duke University
King's College Hospital NHS Trust
University of California, San Diego
Bellicum Pharmaceuticals
Bellicum Pharmaceuticals
Pfizer
University of Virginia
OMNI Medical Services, LLC
Medical College of Wisconsin
Duke University
Children's Mercy Hospital Kansas City
Georgia State University
Emmaus Medical, Inc.
Reprixys Pharmaceutical Corporation
St. Jude Children's Research Hospital
New York Medical College
Brigham and Women's Hospital
Teva Branded Pharmaceutical Products R&D, Inc.
Teva Branded Pharmaceutical Products R&D, Inc.
Endo Pharmaceuticals